Psychedelic Therapeutics Market
Psychedelic Therapeutics Market Size, Share & Trends Analysis Report
Global Psychedelic Drugs Market Size, Share, Trends, Analysis, Segmentation Research Report, By Source (Synthetic and Natural), Type (Empathogens, Dissociatives, and Others), Drugs (Gamma-Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide (LSD), 3,4-MethylEnedioxyMethamphetamine, and Others), Application (Narcolepsy, Treatment Resistant Depression, Major Depressive Disorder, Opiate Addiction, Post-Traumatic Stress Disorder, and Others), Route of Administration (Oral, Inhalation, and Injectable), End-User (Hospitals, Specialty Clinics, Homecare, and Others), Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, and Online Pharmacy) – And Segment Forecasts 2025-2032.
Published
Report ID : BMRC 3499
Number of pages : 300
Published Date : Jul 2025
Category : Healthcare
Delivery Timeline : 48 hrs
Key Players
- Jazz Pharmaceuticals, Inc. (U.S.),
- Janssen Pharmaceuticals, Inc. (U.S.)
- Hikma Pharmaceuticals PLC (U.K.)
- Compass (U.S.)
- Verrian (Germany)
- Pfizer Inc. (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Avadel (Ireland)
- Celon Pharma SA.(Poland)
- Cybin Corp. (Canada)
- GH Research (Ireland)
- Entheon Biomedical Corp (Canada)
- PharmaTher Holdings Ltd. (India)
- NRx Pharmaceuticals, Inc. (U.S.)
- Usona Institute (U.S.)
Market Segmentation
By Source
- Synthetic
- Natural
By Type
- Empathogens
- Dissociatives
- Others
By Drugs
- Gamma-Hydroxybutyric Acid
- Ketamine
- Psilocybin
- Lysergic Acid Diethylamide (LSD)
- 3,4-MethylEnedioxyMethamphetamine
- Others
By Application
- Narcolepsy
- Treatment Resistant Depression
- Major Depressive Disorder
- Opiate Addiction
- Post-Traumatic Stress Disorder
- Others
By Route of Administration
- Oral
- Inhalation
- Injectable
By End-User
- Hospitals
- Specialty Clinics
- Homecare
- Others
By Distribution Channel
- Hospitals Pharmacy
- Retail Pharmacy
- Online Pharmacy
SUMMARY
Segments
Market Segmentation
By Source
- Synthetic
- Natural
By Type
- Empathogens
- Dissociatives
- Others
By Drugs
- Gamma-Hydroxybutyric Acid
- Ketamine
- Psilocybin
- Lysergic Acid Diethylamide (LSD)
- 3,4-MethylEnedioxyMethamphetamine
- Others
By Application
- Narcolepsy
- Treatment Resistant Depression
- Major Depressive Disorder
- Opiate Addiction
- Post-Traumatic Stress Disorder
- Others
By Route of Administration
- Oral
- Inhalation
- Injectable
By End-User
- Hospitals
- Specialty Clinics
- Homecare
- Others
By Distribution Channel
- Hospitals Pharmacy
- Retail Pharmacy
- Online Pharmacy
Regions and Country
North America
- U.S.
- Canada
Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Sweden
- Netherlands
- Turkey
- Switzerland
- Belgium
- Rest of Europe
Asia-Pacific
- South Korea
- Japan
- China
- India
- Australia
- Philippines
- Singapore
- Malaysia
- Thailand
- Indonesia
- Rest of APAC
Latin America
- Mexico
- Colombia
- Brazil
- Argentina
- Peru
- Rest of South America
Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- South Africa
- Rest of MEA
Key Players
Key Players
- Jazz Pharmaceuticals, Inc. (U.S.),
- Janssen Pharmaceuticals, Inc. (U.S.)
- Hikma Pharmaceuticals PLC (U.K.)
- Compass (U.S.)
- Verrian (Germany)
- Pfizer Inc. (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Avadel (Ireland)
- Celon Pharma SA.(Poland)
- Cybin Corp. (Canada)
- GH Research (Ireland)
- Entheon Biomedical Corp (Canada)
- PharmaTher Holdings Ltd. (India)
- NRx Pharmaceuticals, Inc. (U.S.)
- Usona Institute (U.S.)
